T. Rowe Price Investment Management, Inc. Ascendis Pharma A/S Put Options Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
234Shares Held
58.9MCall Options Held
208KPut Options Held
321K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.38 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$788 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$711 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$634 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$597 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.95B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...